secwatch.observer — SEC 8-K summary
======================================

Issuer:     10X Capital Venture Acquisition Corp. III (—)
CIK:        0001848948
Form:       8-K
Filed at:   2024-01-09T23:59:59+00:00
Accession:  0001213900-24-002336
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

10X Capital Venture Acquisition Corp. III announces CEO and President changes; Weisburd named CEO, Ahmed President
--------------------------------------------------------------------------------

- CEO Hans Thomas departed Jan 9, 2024; remains Chairman of the Board.
- David Weisburd appointed CEO, previously COO and Head of Origination.
- President Oliver Wriedt departed; Osman Ahmed appointed President.
- Ahmed executed joinder to insider letter agreement and indemnity agreement.
- Merger with American Gene Technologies (Addimmune) remains pending; S-4 filed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1848948/000121390024002336/0001213900-24-002336-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1848948/000121390024002336/ea191405-8k425_10xcap3.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-002336

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer